Cynapsus Therapeutics

Cynapsus Therapeutics

Cynapsus Therapeutics is a pharmaceutical subsidiary of Sunovion developing a non-injectable rescue therapy for Parkinson’s disease symptoms. The company was founded in 2004 and is headquartered in Toronto, Ontario, Canada.

Cynapsus Therapeutics is a specialty pharmaceutical company developing oral drug treatments for Parkinson's disease. Cynapsus Therapeutics was founded in 1984 by Anthony Giovinazzo and is headquartered in Toronto, Ontario, Canada.

Products

APL-130277

Cynapsus Therapeutic's drug candidate for the treatment of Parkinson's disease is called APL-130277 and is a sublingual form of apomorphine; a common drug used to treat Parkison's disease that is administered to patients through the gastrointestinal system.

Acquired by Sunovion Pharmaceuticals

On September 1, 2016 Sunovion Pharmaceuticals acquired Cynapsus Therapeutics to expand its own drug portfolio to treat diseases on the central nervous system. Sunovion Pharmaceuticals purchased Cynapsus Therapeutics for approximately $624 million at $40.50 per share in cash.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Cynapsus Therapeutics Venture Funding Round March 2015
Venture round
17,262,000
Venrock
Cynapsus Therapeutics Venture Funding Round March 2013
Venture round
4,100,000
Cynapsus Therapeutics Venture Funding Round April 2014
Venture round
14,500,000
Cynapsus Therapeutics Grant July 2014
Grant (money)
500,000
Cynapsus Therapeutics Venture Funding Round March 2012
Venture round
939,500
5 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Andrew Williams

COO & CFO

Anthony J. Giovinazzo

President & CEO, Director

David J. Duff

Employee

Dawson Sprigings

Employee

Dr. Albert Agro

Chief Medical Officer

Kristen Galfetti

Vice President Relations & Corporate Communications

Thierry Bilbault

Chief Scientific Officer and Executive Vice President of Chemistry, Manufacturing, and Controls

Further reading

Title
Author
Link
Type
Date

Why Cynapsus Therapeutics (CYNA) Stock Is Soaring Today

Rachel Aldrich

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.